Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, pharmacokinetic, and pharmacodynamic study of subcutaneous CYB004 in healthy subjects
NL-OMON60396Phase 1Completed
- Sponsor
- Cybin Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of HLP004 in major depressive disorder (MDD) and anxiety disorder, sponsored by Cybin Inc. Started Dec 2023; status: completed.
02
Drugs
HLP004
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NL-OMON60396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60396.